Loading
A phase 2 trial of Taletrectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., active and no longer recruiting.
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC is a phase 2 interventional study registered as NCT04919811 by Nuvation Bio Inc., with 217 participants enrolled, started 2021-09-01 and due to reach its primary completion in 2025-06-11. Interventions recorded: Taletrectinib. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Nuvation Bio, ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/